Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results